Today: 8 June 2026
Home Depot stock slips as housing data brightens — what investors watch next
30 December 2025
2 mins read

Home Depot stock slips as housing data brightens — what investors watch next

NEW YORK, December 29, 2025, 19:17 ET — After-hours

  • Home Depot shares closed down 0.67% at $347.45 and were little changed in after-hours trading.
  • U.S. pending home sales rose 3.3% in November, beating forecasts and reaching the highest level since February 2023, the National Association of Realtors said.
  • Investors are watching Tuesday’s home-price data and Wednesday’s Fed minutes for fresh signals on rates and housing into year-end trading.

Home Depot (HD) shares ended Monday down 0.67% at $347.45 and were little changed in after-hours trading, tracking a broad market dip as investors weighed new housing data and the outlook for rate-sensitive consumer names into year end.

The home-improvement retailer is closely tied to the U.S. housing cycle because moves, remodels and repairs tend to rise when more homes change hands and homeowners feel less squeezed by borrowing costs. Mortgage rates and leading housing indicators have become key inputs for investors trying to pin down the timing of a demand rebound.

That backdrop sharpened on Monday after a report showed pending home sales — contracts signed to buy existing homes — jumped 3.3% in November from October, topping economists’ expectations for a 1.0% rise, Reuters reported. The index hit its strongest level since February 2023.

“Homebuyer momentum is building,” NAR Chief Economist Lawrence Yun said, pointing to improving affordability as mortgage rates eased and wage gains outpaced home prices. National Association of REALTORS®

Pending sales tend to lead existing-home sales because contracts typically convert into closings within one or two months, NAR said — a timeline that could shape early-2026 expectations for housing-linked retailers.

Mortgage rates have been moving in the same direction. Freddie Mac said the average 30-year fixed-rate mortgage fell to 6.18% as of Dec. 24, down from 6.21% a week earlier and 6.85% a year earlier.

Even so, Home Depot has urged patience. Earlier this month, the company outlined a preliminary fiscal 2026 view that implied slower growth than analysts had penciled in, with management citing the lack of a clear housing “inflection” as consumers stayed cautious on big-ticket projects. Reuters+1

Monday’s decline also reflected the tape. The S&P 500 and Dow fell in quiet, holiday-thinned trading, with large-cap decliners weighing on the blue-chip index.

Home Depot’s closest big-box peer, Lowe’s (LOW), also eased on the day, underscoring that investors are still trading the group as a housing proxy rather than on fresh company-specific catalysts.

Home Depot traded between $344.77 and $350.23 in the regular session, with about 3.8 million shares changing hands, and the stock held near the close in extended trading.

Ahead of Tuesday’s session, traders will parse the S&P CoreLogic Case-Shiller home price index for October at 9:00 a.m. ET and Chicago PMI at 9:45 a.m., with the Fed’s December meeting minutes due Wednesday at 2:00 p.m. ET, according to Scotiabank’s calendar.

On the company calendar, Home Depot’s next earnings are expected on Feb. 24, 2026, according to Zacks, when investors will look for updates on comparable sales, demand from professional contractors and the balance between promotional activity and margins as rates and housing turnover set the tone for 2026.

Stock Market Today

  • Markel Group Stock Drops 15.4% YTD Amid Earnings Miss; Analysts See 14.5% Upside
    June 8, 2026, 2:06 PM EDT. Shares of Markel Group Inc. (MKL) have fallen 15.4% year-to-date, underperforming the industry decline of 5.4%, following a first-quarter 2026 earnings miss. Challenges include investment portfolio losses, lower premium volumes, and earnings estimate reductions. Despite these headwinds, MKL's strong underwriting discipline, strategic acquisitions, international diversification, and niche insurance expertise position it for sustainable growth. Analysts' average price target of $2,036.75 indicates a potential 14.5% upside from current levels. MKL trades at a price-to-book value of 1.26, below the industry average of 2.51, with a trailing 12-month return on invested capital of 5.8%, outperforming the industry average of 2.2%. The company aims to double insurance operations, targeting $10 billion premiums and $1 billion underwriting profit in five years, driven by organic growth and acquisitions.

Latest articles

ASML Sets New European Valuation Record; Broadcom Shows Risks in AI

ASML Sets New European Valuation Record; Broadcom Shows Risks in AI

8 June 2026
ASML’s market value soared to a European record of $691.8 billion as analysts raised estimates for its EUV machine output, driving U.S. shares up 7.1% after JPMorgan and Morgan Stanley hiked price targets, with investors betting on ASML’s control of critical chipmaking tools amid surging AI demand and factory expansions planned for 2026.
Meta $145 Billion AI Push Faces Snag With Wall Street

Meta $145 Billion AI Push Faces Snag With Wall Street

8 June 2026
Meta shares fell 0.8% to $587.97 Monday after reports the company may sell tens of billions in new stock to fund AI infrastructure, raising investor concerns about dilution as capital spending soars and AI financing shifts from earnings to equity markets; Meta has not hired banks and may still consider other financing options.
Palantir’s $200 Target Meets Doubts on AI Growth

Palantir’s $200 Target Meets Doubts on AI Growth

8 June 2026
Palantir shares steadied at $135.73 after a volatile week, as investors weighed 85% Q1 revenue growth and a raised 2026 forecast against a steep 96x forward earnings valuation, with analysts warning that any slowdown in U.S. commercial or government revenue, or a shift in AI sentiment, could sharply impact the stock’s high multiple.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Next Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Go toTop